Morphocell Technologies, co-founded by Margaret Bywater, District 3’s Bio Stream Lead, has completed a US$50M Series A to advance its regenerative medicine platform and expand globally. Based in Montreal, Morphocell is developing stem cell–derived tissue therapeutics to offer new options for patients with severe liver disease, aiming to reduce reliance on transplants and improve outcomes worldwide.